Developer docs
API playgroundTry for free, no card

Search company profiles

Saphetor

Full company profile

uuid0002m8s

Namestring
Saphetor
Legal namestring
Saphetor S.A.
Websiteurl
saphetor.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Saphetor S.A. is a privately held Swiss precision medicine company founded in 2014 and headquartered at the EPFL Innovation Park in Lausanne, with regional offices in Boston and Athens and a distributed team across more than ten countries. The company builds the VarSome platform, an AI-enhanced genomic data analysis system that performs variant calling, annotation, classification, visualization, and report generation on next-generation sequencing (NGS) data from whole genomes, exomes, and gene panels. VarSome integrates evidence from 140+ curated data sources (ClinVar, gnomAD, COSMIC, CKB, CIViC, OncoKB, among others) and applies machine learning and natural language processing to structure literature evidence and support phenotype-driven prioritization aligned with ACMG/AMP guidelines.

The product portfolio is organized as a freemium platform-plus-modules architecture. VarSome.com is a freely accessible community and search engine used by 500K+ professionals in 150+ countries, serving as the top-of-funnel acquisition engine and a network-effects asset. Paid tiers include VarSome Premium (individual variant lookups for researchers), VarSome Clinical (CE-IVDR Class C certified and HIPAA-compliant platform for clinical diagnostic labs with on-premises deployment), VarSome API (pipeline integration for bioinformatics groups), and VarSome Insights (real-world clinician search data for pharma feasibility, trial site selection, and patient recruitment). Solution areas span Germline (rare disease diagnostics), Oncology (somatic variant interpretation, biomarker assessment, therapy selection), and Life Sciences (pharma R&D support). The company monetizes via annual subscriptions with quote-driven enterprise pricing; distribution combines direct enterprise sales, regional channel partners (Sciencewerke in SEA, LongSeq in Spain), and an implementation partnership with Platomics for IVDR compliance in the EU.

Saphetor serves clinical laboratories, hospitals and cancer centers, pharmaceutical and biotech organizations, and academic researchers across North America, Europe, Southeast Asia, and Latin America. Named customers include Gencell Pharma (Latin America), PTC Therapeutics (rare disease awareness), SAOL Therapeutics (clinical trial enrollment), and the Veneto Institute of Oncology IOV-IRCCS (liquid biopsy research). The company has accumulated a broad certification stack (CE-IVDR Class C, ISO 13485, ISO 27001:2022, IEC 62304, HDS, GDPR, HIPAA) and is a member of GA4GH, with citations in 5,000-6,000 scientific papers supporting its domain authority. Disclosed funding totals approximately $6.6M across five rounds since 2015, with the most recent ($4.2M) in March 2020.

Short descriptiontext

Saphetor is a Swiss precision medicine company that builds the AI-enhanced VarSome platform for genomic variant interpretation, serving clinical laboratories, hospitals, pharmaceutical organizations, and researchers across more than 150 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLausanne, Switzerland
HQ citystring
Lausanne
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
genomic variant interpretation, NGS data annotation, clinical genomics software, precision medicine platform, bioinformatics analysis tools
Industry3 codes
PRIMARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLACANAM
DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code3 codes
  • Software Publishers5132
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services518
SIC code1 code
  • Services-Computer Programming, Data Processing, Etc.7370
Product category
Clinical Genomics Software
Social media profiles2 records
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model3 records
1VarSome Subscription Tiers
TypeSubscription Recurring
Description

VarSome Professional is a subscription service with premium data resources and features. VarSome Premium and VarSome Clinical are professional editions with sophisticated data-mining and analysis tools. VarSome API provides cloud-based or on-premises installations for bioinformatics groups.

saphetor.com
2VarSome.com Free Tier
TypeFreemium
Description

VarSome.com professional community and search engine is freely accessible with community-driven knowledge base. Generates network effects and drives premium tier conversions.

saphetor.com
3Enterprise Licensing
TypeSubscription Recurring
Description

VarSome Clinical is offered as IVDR-certified and HIPAA-compliant fully-fledged platform, with on-premises installation options for organizations with restrictive data regulations.

saphetor.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Pricing details5 tiers
1VarSome.com - Free community access
ModelFreemiumBilling cadenceOthers
Notes

Freely accessible professional community and search engine for variant interpretation

saphetor.com
2VarSome Professional - Full suite variant interpretation tools
ModelSubscriptionBilling cadenceAnnual
Notes

For labs analyzing NGS data in research or clinical environment

saphetor.com
3VarSome Premium - Individual gene or variant lookups
ModelSubscriptionBilling cadenceAnnual
Notes

For researchers needing variant lookups with integrated evidence from multiple databases

saphetor.com
4VarSome Clinical - CE-IVD certified clinical platform
ModelSubscriptionBilling cadenceAnnual
Notes

For labs generating NGS data; CE IVD-certified and HIPAA-compliant; brings VarSome power to Illumina and BGI FASTQs and any VCFs

saphetor.com
5VarSome API - Pipeline integration
ModelSubscriptionBilling cadenceAnnual
Notes

For bioinformatics groups integrating VarSome database and classifiers into existing in-house pipelines through cloud-based or on-premises installations

saphetor.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1VarSome
Description

Comprehensive platform for genomic variant interpretation and analysis, including VarSome Community, VarSome Premium, VarSome Clinical, VarSome API, and VarSome Insights

saphetor.com
+4 more records
Core offering1 text field

Saphetor develops and sells the VarSome suite, an AI-enhanced genomic data analysis platform that performs variant calling, annotation, classification, visualization, and report generation for next-generation sequencing (NGS) data. The suite includes a freely accessible community platform (VarSome.com), professional subscription tiers (VarSome Premium, VarSome Clinical), an integration API (VarSome API), and a real-world search data product (VarSome Insights) for pharmaceutical and biotech customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Tumor fraction (TF) dynamics can anticipate clinical outcomes early in treatment using combined sWGS and targeted NGS with VarSome Premium
+2 more records
Product overview1 text field

Saphetor's VarSome Suite is a platform-plus-modules architecture centered on the VarSome platform for genomic variant interpretation. The core platform (VarSome.com) provides a freely accessible community-driven knowledge base, while professional tiers include VarSome Premium (subscription for individual lookups), VarSome Clinical (CE-IVD certified clinical platform), VarSome API (pipeline integration), and VarSome Insights (real-world search data for pharma). The platform is organized into three solution areas: Germline (hereditary variants), Oncology (tumor sequencing), and Life Sciences (pharmaceutical R&D). The platform integrates 140+ curated data sources and supports both short-read (Illumina, BGI) and long-read (Oxford Nanopore) sequencing data.

Product and service5 records
1VarSome.com
CategoryCommunity / freemium platform
Description

Freely accessible community-driven variant search engine and knowledge base for professional human genetics, enabling flexible queries across genetic and genomic data resources for researchers and clinicians.

2VarSome Premium
CategorySubscription software tier
Description

Professional subscription service providing premium data resources and features for researchers needing individual gene or variant lookups, biomarker discovery, and exploratory analyses integrated with curated genomic databases.

3VarSome Clinical
CategoryClinical diagnostics software
Description

CE-IVD certified and HIPAA-compliant clinical platform for variant discovery, annotation, and interpretation of NGS data from whole genomes, exomes, and gene panels, enabling fast and accurate diagnostic decisions for laboratories and hospitals.

4VarSome API
CategoryDeveloper API / integration product
Description

API product enabling bioinformatics groups to integrate the VarSome database and classifiers into existing in-house pipelines via cloud-based or on-premises installations, allowing teams to focus on analysis rather than database management.

5VarSome Insights
CategoryReal-world data / analytics product
Description

Real-world clinician search data platform supporting feasibility studies, clinical trial site identification, patient recruitment, and post-marketing awareness for pharmaceutical and biotech organizations.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-10-17
Description

Sciencewerke appointed as official distributor for VarSome in Australia, Malaysia, Singapore, and Thailand. Sciencewerke is a leading provider of biomedical and life science solutions operating in Southeast Asia, committed to supporting cutting-edge research and diagnostics with products in Cellomics, Genomics, Proteomics, and Bio-imaging.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-07-30
Description

Saphetor and LongSeq partner to expand access to advanced long-read sequencing diagnostics in Spain. LongSeq is a Spanish biotechnology company specialized in advanced long-read DNA sequencing using Oxford Nanopore Technologies, offering HEREDITARY-CANCER-Seq test for comprehensive variant detection including structural and epigenetic variants.

3Platomics
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2024-09-09
Description

Saphetor and Platomics team up to offer selected EU clinical labs an efficient regulatory platform for documenting and validating in-house NGS tests in compliance with IVDR. The PlatoX platform provides structured files, integrated guidance, and rules-based automation for IVDR documentation requirements.

saphetor.com
4Gencell Pharma
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Gencell Pharma, a leading genomics company in Latin America providing advanced sequencing and molecular diagnostics. Partnership helps Gencell expand capacity, improve quality, and deliver reliable results to patients and clinicians across the region. VarSome supports accuracy in variant interpretation, increases speed in data processing, and strengthens collaboration.

saphetor.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration leveraging Saphetor's innovative approach to bring together the global genomics community to build awareness in rare disease programs.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership enabled SAOL Therapeutics to reach out to clinicians in relevant regions and accelerate clinical trial enrollment, facilitating connections with potential participants based on variant-search activity through VarSome Insights.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-driven clinical genomics analysis platform serving hospitals, labs, and pharma with multimodal NGS interpretation. Directly comparable to VarSome Clinical on customer base, AI-led interpretation, and CE-IVD positioning.

TypeDirect peer
Description

Clinical genomic variant interpretation platform for rare disease and somatic oncology, sold to labs and hospitals. Closely comparable product (annotated variant interpretation) and customer overlap (clinical labs, hospitals).

TypeDirect peer
Description

Clinical genomics interpretation platform with AI-driven variant classification for hereditary disease and oncology. Directly comparable on ACMG-aligned interpretation, lab customers, and enterprise clinical sales motion.

TypeDirect peer
Description

Genomics analysis platform formed from Seven Bridges and PierianDx, offering clinical NGS interpretation, biomarker discovery, and pharma genomics tools. Comparable on clinical interpretation workflows and pharma/biotech customers.

TypeDirect peer
Description

Cloud-based genomics data management and analysis platform used by clinical labs, hospitals, and pharma. Comparable on data infrastructure, NGS pipeline integration, and pharma R&D customers.

TypeBroad incumbent
Description

Dominant sequencing instrument vendor that bundles DRAGEN secondary analysis and BaseSpace interpretation with its instruments and reagents. Overlaps with VarSome on secondary and tertiary NGS analysis for the same lab customers.

TypeBroad incumbent
Description

Provider of QCI Interpret and Ingenuity Pathway Analysis for clinical and research variant interpretation. Directly comparable tertiary analysis product for clinical labs and broad pharma use.

TypeEmerging player
Description

Cloud genomics and biomedical data platform focused on federated analysis for clinical and pharma customers. Comparable on cloud-native genomics infrastructure and pharma/biotech data products, but with a more infrastructure-led angle.

TypeEmerging player
Description

Genomics data and real-world evidence platform serving pharma and precision medicine customers. Comparable on RWE-style pharma data products overlapping with VarSome Insights.

10Tempus Labs
TypeBroad incumbent
Description

AI-enabled precision medicine platform combining NGS testing with proprietary data library for oncology and pharma R&D. Comparable on clinical oncology interpretation, pharma data licensing, and biomarker-driven trial support.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance10 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Saphetor

Clinical Genomics Softwaresaphetor.com

Saphetor is a Swiss precision medicine company that builds the AI-enhanced VarSome platform for genomic variant interpretation, serving clinical laboratories, hospitals, pharmaceutical organizations, and researchers across more than 150 countries.

What Saphetor does

Saphetor S.A. is a privately held Swiss precision medicine company founded in 2014 and headquartered at the EPFL Innovation Park in Lausanne, with regional offices in Boston and Athens and a distributed team across more than ten countries. The company builds the VarSome platform, an AI-enhanced genomic data analysis system that performs variant calling, annotation, classification, visualization, and report generation on next-generation sequencing (NGS) data from whole genomes, exomes, and gene panels. VarSome integrates evidence from 140+ curated data sources (ClinVar, gnomAD, COSMIC, CKB, CIViC, OncoKB, among others) and applies machine learning and natural language processing to structure literature evidence and support phenotype-driven prioritization aligned with ACMG/AMP guidelines.

The product portfolio is organized as a freemium platform-plus-modules architecture. VarSome.com is a freely accessible community and search engine used by 500K+ professionals in 150+ countries, serving as the top-of-funnel acquisition engine and a network-effects asset. Paid tiers include VarSome Premium (individual variant lookups for researchers), VarSome Clinical (CE-IVDR Class C certified and HIPAA-compliant platform for clinical diagnostic labs with on-premises deployment), VarSome API (pipeline integration for bioinformatics groups), and VarSome Insights (real-world clinician search data for pharma feasibility, trial site selection, and patient recruitment). Solution areas span Germline (rare disease diagnostics), Oncology (somatic variant interpretation, biomarker assessment, therapy selection), and Life Sciences (pharma R&D support). The company monetizes via annual subscriptions with quote-driven enterprise pricing; distribution combines direct enterprise sales, regional channel partners (Sciencewerke in SEA, LongSeq in Spain), and an implementation partnership with Platomics for IVDR compliance in the EU.

Saphetor serves clinical laboratories, hospitals and cancer centers, pharmaceutical and biotech organizations, and academic researchers across North America, Europe, Southeast Asia, and Latin America. Named customers include Gencell Pharma (Latin America), PTC Therapeutics (rare disease awareness), SAOL Therapeutics (clinical trial enrollment), and the Veneto Institute of Oncology IOV-IRCCS (liquid biopsy research). The company has accumulated a broad certification stack (CE-IVDR Class C, ISO 13485, ISO 27001:2022, IEC 62304, HDS, GDPR, HIPAA) and is a member of GA4GH, with citations in 5,000-6,000 scientific papers supporting its domain authority. Disclosed funding totals approximately $6.6M across five rounds since 2015, with the most recent ($4.2M) in March 2020.

Saphetor firmographics

Firmographics
Name
Saphetor
Legal name
Saphetor S.A.
Website
https://saphetor.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
Saphetor is a Swiss precision medicine company that builds the AI-enhanced VarSome platform for genomic variant interpretation, serving clinical laboratories, hospitals, pharmaceutical organizations, and researchers across more than 150 countries.
Ownership category
akta.pro rank

Saphetor industry classification

Industry
Product category
Clinical Genomics Software
NAICS
Software Publishers (5132), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (518)
SIC
Services-Computer Programming, Data Processing, Etc. (7370)
akta.pro industry
PRIMARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLACANAM
DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Genomic variant interpretation
  • NGS data annotation
  • Clinical genomics software
  • Precision medicine platform
  • Bioinformatics analysis tools

Where Saphetor is headquartered

Location

Headquarters

HQ city
Lausanne
HQ country
Switzerland
HQ region
Europe

Offices3 records

Markets served

Saphetor business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. VarSome Subscription Tiers: VarSome Professional is a subscription service with premium data resources and features. VarSome Premium and VarSome Clinical are professional editions with sophisticated data-mining and analysis tools. VarSome API provides cloud-based or on-premises installations for bioinformatics groups.
  2. VarSome.com Free Tier: VarSome.com professional community and search engine is freely accessible with community-driven knowledge base. Generates network effects and drives premium tier conversions.
  3. Enterprise Licensing: VarSome Clinical is offered as IVDR-certified and HIPAA-compliant fully-fledged platform, with on-premises installation options for organizations with restrictive data regulations.

Pricing tiers

ModelBillingPrice
FreemiumOthersVarSome.com - Free community access
SubscriptionAnnualVarSome Professional - Full suite variant interpretation tools
SubscriptionAnnualVarSome Premium - Individual gene or variant lookups
SubscriptionAnnualVarSome Clinical - CE-IVD certified clinical platform
SubscriptionAnnualVarSome API - Pipeline integration

Go-to-market motion4 records

Distribution channels5 records

Marketing channels5 records

Saphetor product offering

Product offering

Core offering

Saphetor develops and sells the VarSome suite, an AI-enhanced genomic data analysis platform that performs variant calling, annotation, classification, visualization, and report generation for next-generation sequencing (NGS) data. The suite includes a freely accessible community platform (VarSome.com), professional subscription tiers (VarSome Premium, VarSome Clinical), an integration API (VarSome API), and a real-world search data product (VarSome Insights) for pharmaceutical and biotech customers.

Product overview

Saphetor's VarSome Suite is a platform-plus-modules architecture centered on the VarSome platform for genomic variant interpretation. The core platform (VarSome.com) provides a freely accessible community-driven knowledge base, while professional tiers include VarSome Premium (subscription for individual lookups), VarSome Clinical (CE-IVD certified clinical platform), VarSome API (pipeline integration), and VarSome Insights (real-world search data for pharma). The platform is organized into three solution areas: Germline (hereditary variants), Oncology (tumor sequencing), and Life Sciences (pharmaceutical R&D). The platform integrates 140+ curated data sources and supports both short-read (Illumina, BGI) and long-read (Oxford Nanopore) sequencing data.

Differentiator

Problem solved

Functional benefit

Brands

  • VarSome: Comprehensive platform for genomic variant interpretation and analysis, including VarSome Community, VarSome Premium, VarSome Clinical, VarSome API, and VarSome Insights
  • VarSome Clinical
  • VarSome Premium
  • VarSome API
  • VarSome Insights

Products and services

  • VarSome.com Freely accessible community-driven variant search engine and knowledge base for professional human genetics, enabling flexible queries across genetic and genomic data resources for researchers and clinicians.
  • VarSome Premium Professional subscription service providing premium data resources and features for researchers needing individual gene or variant lookups, biomarker discovery, and exploratory analyses integrated with curated genomic databases.
  • VarSome Clinical CE-IVD certified and HIPAA-compliant clinical platform for variant discovery, annotation, and interpretation of NGS data from whole genomes, exomes, and gene panels, enabling fast and accurate diagnostic decisions for laboratories and hospitals.
  • VarSome API API product enabling bioinformatics groups to integrate the VarSome database and classifiers into existing in-house pipelines via cloud-based or on-premises installations, allowing teams to focus on analysis rather than database management.
  • VarSome Insights Real-world clinician search data platform supporting feasibility studies, clinical trial site identification, patient recruitment, and post-marketing awareness for pharmaceutical and biotech organizations.

Quantifiable outcome

  • Tumor fraction (TF) dynamics can anticipate clinical outcomes early in treatment using combined sWGS and targeted NGS with VarSome Premium
  • +2 more outcomes

Companies that use Saphetor

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Saphetor technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Saphetor partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • SciencewerkecoreChannel Partner/ Reseller/ Distributor · 17 October 2025Sciencewerke appointed as official distributor for VarSome in Australia, Malaysia, Singapore, and Thailand. Sciencewerke is a leading provider of biomedical and life science solutions operating in Southeast Asia, committed to supporting cutting-edge research and diagnostics with products in Cellomics, Genomics, Proteomics, and Bio-imaging.
  • LongSeqcoreChannel Partner/ Reseller/ Distributor · 30 July 2025Saphetor and LongSeq partner to expand access to advanced long-read sequencing diagnostics in Spain. LongSeq is a Spanish biotechnology company specialized in advanced long-read DNA sequencing using Oxford Nanopore Technologies, offering HEREDITARY-CANCER-Seq test for comprehensive variant detection including structural and epigenetic variants.
  • PlatomicscoreImplementation/ SI/ Consulting Partner · 9 September 2024Saphetor and Platomics team up to offer selected EU clinical labs an efficient regulatory platform for documenting and validating in-house NGS tests in compliance with IVDR. The PlatoX platform provides structured files, integrated guidance, and rules-based automation for IVDR documentation requirements.
  • Gencell PharmacoreStrategic or Co-development PartnerGencell Pharma, a leading genomics company in Latin America providing advanced sequencing and molecular diagnostics. Partnership helps Gencell expand capacity, improve quality, and deliver reliable results to patients and clinicians across the region. VarSome supports accuracy in variant interpretation, increases speed in data processing, and strengthens collaboration.
  • PTC TherapeuticsminorStrategic or Co-development PartnerCollaboration leveraging Saphetor's innovative approach to bring together the global genomics community to build awareness in rare disease programs.
  • SAOL TherapeuticsminorStrategic or Co-development PartnerPartnership enabled SAOL Therapeutics to reach out to clinicians in relevant regions and accelerate clinical trial enrollment, facilitating connections with potential participants based on variant-search activity through VarSome Insights.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Saphetor competitors and assessment

Company assessment

Direct peers

  • Sophia Genetics: AI-driven clinical genomics analysis platform serving hospitals, labs, and pharma with multimodal NGS interpretation. Directly comparable to VarSome Clinical on customer base, AI-led interpretation, and CE-IVD positioning.
  • Congenica: Clinical genomic variant interpretation platform for rare disease and somatic oncology, sold to labs and hospitals. Closely comparable product (annotated variant interpretation) and customer overlap (clinical labs, hospitals).
  • Fabric Genomics: Clinical genomics interpretation platform with AI-driven variant classification for hereditary disease and oncology. Directly comparable on ACMG-aligned interpretation, lab customers, and enterprise clinical sales motion.
  • Velsera: Genomics analysis platform formed from Seven Bridges and PierianDx, offering clinical NGS interpretation, biomarker discovery, and pharma genomics tools. Comparable on clinical interpretation workflows and pharma/biotech customers.
  • DNAnexus: Cloud-based genomics data management and analysis platform used by clinical labs, hospitals, and pharma. Comparable on data infrastructure, NGS pipeline integration, and pharma R&D customers.

Broad incumbents

  • Illumina (BaseSpace, DRAGEN): Dominant sequencing instrument vendor that bundles DRAGEN secondary analysis and BaseSpace interpretation with its instruments and reagents. Overlaps with VarSome on secondary and tertiary NGS analysis for the same lab customers.
  • Qiagen Digital Insights: Provider of QCI Interpret and Ingenuity Pathway Analysis for clinical and research variant interpretation. Directly comparable tertiary analysis product for clinical labs and broad pharma use.
  • Tempus Labs: AI-enabled precision medicine platform combining NGS testing with proprietary data library for oncology and pharma R&D. Comparable on clinical oncology interpretation, pharma data licensing, and biomarker-driven trial support.

Emerging players

  • Lifebit: Cloud genomics and biomedical data platform focused on federated analysis for clinical and pharma customers. Comparable on cloud-native genomics infrastructure and pharma/biotech data products, but with a more infrastructure-led angle.
  • BC Platforms: Genomics data and real-world evidence platform serving pharma and precision medicine customers. Comparable on RWE-style pharma data products overlapping with VarSome Insights.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Saphetor social profiles

Digital presence

Saphetor compliance and trust

Trust signal

Compliance10 records

Saphetor financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Saphetor leadership team

Management profile

Number of profiles

Profiles3 records

Saphetor subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Saphetor funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Saphetor M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Saphetor

What does Saphetor do?

Saphetor develops and sells the VarSome suite, an AI-enhanced genomic data analysis platform that performs variant calling, annotation, classification, visualization, and report generation for next-generation sequencing (NGS) data. The suite includes a freely accessible community platform (VarSome.com), professional subscription tiers (VarSome Premium, VarSome Clinical), an integration API (VarSome API), and a real-world search data product (VarSome Insights) for pharmaceutical and biotech customers.

Is Saphetor a public or private company?

Saphetor is a private company. It is classified as venture growth investor backed and is currently operating.

When was Saphetor founded?

Saphetor was founded in 2014. It employs 51 to 100 people.

Where is Saphetor based?

Saphetor is headquartered in Lausanne, Switzerland, in the Europe region.

How does Saphetor make money?

Three revenue lines are on record. VarSome Subscription Tiers are the primary driver. The others are varSome.com Free Tier and enterprise Licensing.

Who are Saphetor's main competitors?

Direct peers on record are Sophia Genetics, Congenica, Fabric Genomics, Velsera and DNAnexus. Broad incumbents are Illumina (BaseSpace, DRAGEN), Qiagen Digital Insights and Tempus Labs. Emerging players are Lifebit and BC Platforms.

Does Saphetor have an API?

Yes. VarSome API enables bioinformatics groups to integrate the VarSome database and classifiers into existing in-house pipelines. Available via cloud-based or on-premises installations. Allows teams to focus on analysis rather than database management by connecting to VarSome's annotation and classification capabilities directly.

What industry is Saphetor in?

Saphetor's product category is Clinical Genomics Software. Its primary akta.pro industry code is HLAGANAA, Genomics & Next-Generation Sequencing (NGS) Services, with a secondary code of HLAGAEAD, Genomics & Molecular Diagnostics (Trial Support). Its NAICS code is 5132 and its SIC code is 7370.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FortunebusinessinsightsVariant Interpretation Software Market Size, ShareThe global variant interpretation software market was valued at USD 570.1 million in 2025 and is projected to reach USD 1,782.4 million by 2034, growing at a CAGR of 13.07% during the forecast period. The market growth is driven by increasing adoption of Next-Generation Sequencing in clinical diagnostics, rising demand for personalized medicine, and technological advancements in cloud-based tertiary analysis suites. Key industry developments include product launches by QIAGEN, Illumina, and Saphetor SA, as well as strategic partnerships such as GenDX's acquisition of Fabric Genomics and SOPHiA GENETICS' partnership with MD Anderson Cancer Center.Business Wire BlogSaphetor SA receives IVDR Certification for clinical diagnosis support NGS data analysis platform, VarSome Clinical, ensuring enhanced safety and performance standardsSaphetor SA received IVDR certification for its VarSome Clinical platform, approved by TÜV SÜD. The certification ensures compliance with EU medical device regulations, including safety, performance, and post-market surveillance. It marks a shift from research-use-only tools to routine clinical care.ContractpharmaSaphetor, ICON Partner to Develop Precision Medicine Clinical Trial StrategiesSaphetor and ICON are partnering to develop precision medicine clinical trial strategies, leveraging Saphetor's VarSome Insights platform. The collaboration aims to improve trial planning and execution, offering users opt-in data sharing and educational materials on genetic variants. Both companies seek to enhance patient recruitment and trial effectiveness.NatureUnlocking the power of variants through globalized discovery and prioritizationSaphetor, a precision medicine company, built VarSome, a platform for human genome variant identification and interpretation. It serves over 400,000 professional users and integrates more than 130 genomic databases and 32 million publications. The company aims to accelerate variant discovery and improve disease diagnosis and treatment.ForbesThe U.K. Genomics Startups Changing The Future Of Healthcare ForeverThe U.K. genomics industry, worth over £5 billion, is highlighted by startups like Saphetor, Genomics plc, Sano Genetics, and MiNA Therapeutics. These companies use genomic data for disease diagnosis, risk prediction, and drug discovery, with funding ranging from pre-seed to Series A rounds.startupticker.chSaphetor and Roche join forcesSaphetor signed a partnership with Roche Turkey to connect labs for Spinal Muscular Atrophy drug discovery. The collaboration uses Saphetor's VarSome platform, accessible in over 25 countries, to accelerate scientific collaboration. The goal is to foster relationships and accelerate SMA research.InsideprecisionmedicineDNAnexus, Saphetor Partner on Genomic Analysis SolutionDNAnexus and Saphetor announced a partnership to build a sample-in, report-out genomic analysis solution combining DNAnexus' cloud platform with Saphetor's variant annotation engine. The solution integrates over 30 databases with more than 33 billion variant annotation points, enabling secure whole-genome analysis. The companies aim to accelerate precision medicine by moving from NGS data analysis to interpretation.startupticker.chSaphetor inks agreement with AurigenSaphetor SA, a Swiss precision-medicine company, signed a pay-per-use service agreement with Aurigen SA, a genetic pathology lab. Aurigen will use Saphetor's platform to improve diagnostic accuracy and turnaround time for cancer patients. Saphetor's VarSome.com search engine has over 33 billion data points.startupticker.chSaphetor Signs Multiple Service Agreements with University College LondonSaphetor, a Swiss precision medicine company, signed service agreements with University College London's Exome Consortium. The partnership will use Saphetor's platform to investigate eye disorders, aiming to improve genetic diagnoses and identify patients for clinical trials. The company intends to accelerate novel research findings on multiple projects.